Pramlintide and the treatment of diabetes: a review of the data since its introduction.

  title={Pramlintide and the treatment of diabetes: a review of the data since its introduction.},
  author={Lisa M. Younk and Maia Mikeladze and Stephen Neil Davis},
  journal={Expert opinion on pharmacotherapy},
  volume={12 9},
INTRODUCTION Postprandial glucose excursions negatively affect glycemic control and markers of cardiovascular health. Pramlintide, an amylinomimetic, is approved for treatment of elevated postprandial glucose levels in type 1 and type 2 diabetes mellitus. AREAS COVERED A literature search of PubMed was conducted to locate articles (up to January 2011) pertaining to original preclinical and clinical research and reviews of amylin and pramlintide. Additional sources were selected from reference… CONTINUE READING
23 Citations
84 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 23 extracted citations


Publications referenced by this paper.
Showing 1-10 of 84 references

Clinical studies

  • A. Young
  • Adv Pharmacol
  • 2005
Highly Influential
4 Excerpts

Amylin and Takeda voluntarily suspend clinical activities in obesity

  • BS Affiliation Lisa M Younk, MD Maia Mikeladze, N DavisStephen
  • Room N3W42,
  • 2011
1 Excerpt

Pharmacokinetics and hyperglycaemic effects of the amylin analogue, AC137, in man [abstract

  • C Moyses, O Kolterman, T. Mant
  • Diabet Med 1993;10:S25 Younk, Mikeladze & Davis…
  • 2011
2 Excerpts

Similar Papers

Loading similar papers…